| Literature DB >> 35327534 |
Lucie Larigot1, Daniel Mansuy2, Ilona Borowski2, Xavier Coumoul1, Julien Dairou2.
Abstract
Caenorhabditis elegans is an important model used for many aspects of biological research. Its genome contains 76 genes coding for cytochromes P450 (P450s), and few data about the biochemical properties of those P450s have been published so far. However, an increasing number of articles have appeared on their involvement in the metabolism of xenobiotics and endobiotics such as fatty acid derivatives and steroids. Moreover, the implication of some P450s in various biological functions of C. elegans, such as survival, dauer formation, life span, fat content, or lipid metabolism, without mention of the precise reaction catalyzed by those P450s, has been reported in several articles. This review presents the state of our knowledge about C. elegans P450s.Entities:
Keywords: cytochrome P450; predictive toxicology; worm nematode; xenobiotics
Mesh:
Substances:
Year: 2022 PMID: 35327534 PMCID: PMC8945457 DOI: 10.3390/biom12030342
Source DB: PubMed Journal: Biomolecules ISSN: 2218-273X
Genes and pseudogenes (in italics) of P450s in C. elegans.
| Family | Transcript | Transcript | Protein | Protein |
|---|---|---|---|---|
| 13 | T10B9.8.1 | 1771 | CYP-13A1 | 519 |
| T10B9.7.1 | 2258 | CYP-13A2 | 515 | |
| T10B9.5.1 | 1677 | CYP-13A3 | 520 | |
| T10B9.1.1 | 1655 | CYP-13A4 | 520 | |
| T10B9.2.1 | 1665 | CYP-13A5 | 520 | |
| T10B9.3.1 | 1759 | CYP-13A6 | 518 | |
| T10B9.10.1 | 1623 | CYP-13A7 | 518 | |
| T10B9.4.1 | 1594 | CYP-13A8 | 509 | |
|
|
|
| ||
| ZK1320.4.1 | 1680 | CYP-13A10 | 519 | |
| F14F7.2.1 | 1653 | CYP-13A11 | 517 | |
| F14F7.3.1 | 1726 | CYP-13A12 | 518 | |
| F02C12.5.1 | 1652 | CYP-13B1 | 510 | |
| K06G5.2.1 | 1786 | CYP-13B2 | 511 | |
| 14 | K09A11.2.1 | 1533 | CYP-14A1 | 491 |
| K09A11.3.1 | 1535 | CYP-14A2 | 492 | |
| K09A11.4.1 | 1541 | CYP-14A3 | 498 | |
| R04D3.1.1 | 1549 | CYP-14A4 | 491 | |
| F08F3.7.1 | 1561 | CYP-14A5 | 492 | |
| 22 | T13C5.1 | 1999 | CYP-22A1 (daf-9) | 572 |
| 23 | B0304.3.1 | 1719 | CYP-23A1 | 534 |
| 25 | C36A4.1 | 1631 | CYP-25A1 | 502 |
| C36A4.2 | 1570 | CYP-25A2 | 502 | |
| C36A4.3 | 1775 | CYP-25A3 | 502 | |
| C36A4.6 | 1677 | CYP-25A4 | 501 | |
|
|
|
| ||
| K06B9.1 | 708 | CYP-25A6 | 236 | |
| 29 |
|
|
| |
| T19B10.1 | 1733 | CYP-29A2 | 503 | |
| Y38C9B.1 | 1743 | CYP-29A3 | 503 | |
| B0331.1 | 1682 | CYP-29A4 | 502 | |
| 31 |
|
|
| |
| H02I12.8 | 1631 | CYP-31A2 | 495 | |
| Y17G9B.3 | 1597 | CYP-31A3 | 495 | |
| Y62E10A.15b2 3 | 1077 | CYP-31A5 | 308 | |
| 32 | C26F1.2 | 1691 | CYP-32A1 | 529 |
| Y5H2B.5 | 1648 | CYP-32B1 | 516 | |
| 33 | C12D5.7 | 1591 | CYP-33A1 | 492 |
| C25E10.21 | 1491 | CYP-33B1 | 496 | |
| C45H4.21 | 1739 | CYP-33C1 | 495 | |
| C45H4.17a2 | 1585 | CYP-33C2 | 495 | |
| F41B5.4 | 1784 | CYP-33C3 | 500 | |
| F44C8.1 | 1583 | CYP-33C4 | 493 | |
| F41B5.3a.1 | 1568 | CYP-33C5 | 494 | |
| F41B5.7a1 | 1778 | CYP-33C6 | 494 | |
| F41B5.4 | 1560 | CYP-33C7 | 494 | |
| R08F11.3 | 1667 | CYP-33C8 | 494 | |
| C50H11.15 | 1616 | CYP-33C9 | 496 | |
| Y49C4A.9 | 1738 | CYP-33C11 | 495 | |
| Y5H2B.61 | 2035 | CYP-33C12 | 426 | |
| K05D4.4 | 1597 | CYP-33D1 | 492 | |
| Y17D7A.41 2 | 1579 | CYP-33D3 | 495 | |
| C49C8.41 | 1753 | CYP-33E1 | 494 | |
| F42A9.51 | 1687 | CYP-33E2 | 494 | |
| F42A9.4 | 890 | CYP-33E3 | 236 | |
| 34 | T10H4.10 | 1595 | CYP-34A1 | 504 |
| T10H4.11 | 1766 | CYP-34A2 | 502 | |
|
|
|
| ||
| T09H2.1.1 | 1680 | CYP-34A4 | 500 | |
| B0213.10 | 1591 | CYP-34A5 | 499 | |
| B0213.11 | 1722 | CYP-34A6 | 498 | |
| B0213.12 | 1579 | CYP-34A7 | 499 | |
| B0213.14 | 1584 | CYP-34A8 | 499 | |
| B0213.15 | 1665 | CYP-34A9 | 516 | |
| B0213.16 | 1571 | CYP-34A10 | 499 | |
| 35 | C03G6.14 | 1546 | CYP-35A1 | 494 |
| C03G6.15 | 1588 | CYP-35A2 | 494 | |
| K09D9.2 | 587 | CYP-35A3 | 494 | |
| C49G7.8 | 1552 | CYP-35A4 | 494 | |
| K07C6.5 | 1727 | CYP-35A5 | 494 | |
| K07C6.4 | 1648 | CYP-35B1 | 499 | |
| K07C6.3 | 1621 | CYP-35B2 | 499 | |
| K07C6.2 | 1500 | CYP-35B3 | 499 | |
| C06B3.3 | 1534 | CYP-35C1 | 495 | |
| F14H3.10 | 1576 | CYP-35D1 | 499 | |
|
|
|
| ||
| 36 | C34B7.3 | 1750 | CYP-36A1 | 493 |
| 37 | F01D5.9 | 1561 | CYP-37A1 | 508 |
| F28G4.1 | 1736 | CYP-37B1 | 509 | |
| 42 | Y80D3A.5 | 1826 | CYP-42A1 | 511 |
| 43 | E03E2.1 | 1698 | CYP-43A1 | 526 |
| 44 | ZK177.5 | 1551 | CYP-44A1 | 489 |
Figure 1Phylogenetic tree gathering human and C. elegans P450s. The square boxes represent human P450s, while the filled round boxes represent C. elegans P450s. Different colors are assigned according to the clan to which the CYP450s belong.
Implication of P450s in biological functions of C. elegans.
| Biological Functions | P450s | Ref. |
|---|---|---|
| Survival/life span | 22A1 | [ |
| Morphology | 22A1, 33E2 | [ |
| Embryonic development | 22A1,31A2, 31A3 | [ |
| Larval development | 22A1, 32A1, 32B1, 33B1, 33C1, 33C2, 33D1 | [ |
| Dauer formation | 13A5, 13A7, 14A1, 14A3, 22A1, 29A3, 32A1, 32B1, 33B1, 33C1, 33C2, 33D1, 33E2, 34A2, 34A5, 34A6, 34A7, 34A8, 34A9, 35B1, 35B2 | [ |
| Reproduction | 31A2, 31A3, 35A2 | [ |
| Fat content | 29A3, 31A2, 31A3, 33E2, 35A1, 35A2, 35A3, 35A4, 35A5 | [ |
| Lipid metabolism | 13A12, 22A1, 29A3, 31A2, 31A3, 33E2, 35A1, 35A2, 35A4, 35A5, 37B1 | [ |
Implication of P450s in the metabolism of endogenous compounds in C. elegans.
| Endobiotics | Metabolite(s) | Reaction(s) | P450(s) Involved | Ref. |
|---|---|---|---|---|
| EPA | 17,18-epoxy-eicosatetraenoic acid | Epoxidation | 13A12, 29A3, 33E2 | [ |
| AA | 19-hydroxy-AA | C-H bond hydroxylation | 33E2 | [ |
| AA | 14,15-epoxy-eicosatrienoic acid | Epoxidation | 13A12 | [ |
| Cholesten-3-ones | Dafachronic acids | Oxidation of CH3 to COOH | 22A1 (DAF-9) | [ |
Figure 2P450 22A1 (DAF-9) catalyzed oxidation of cholesten-3-ones into dafachronic acids.
Induction of C. elegans P450s by xenobiotics.
| Chemical Class | Compounds | P450s Induced | Ref. |
|---|---|---|---|
| Alcohol | Ethanol | 13A12, 13B1, 25A1, 25A2, 29A2, 32B1, 33B1, 33C6, 34A4, 34A6, 35A3, 35A5, 35B1, 35B2, 35C1, 36A1, 37B1 | [ |
| Alkaloid | Caffeine | 13A8, 13A12, 14A1, 14A2, 14A4, 14A5, 32A1, 33C3, 33C4, 33C6, 33C7, 33C9, 33E1, 33E2, 33E3,33E4, 34A7, 34A9, 35A2, 35A3, 35A4, 35A5, 35B1, 35B2, 43A1 | [ |
| Aromatic compound | Ethidium bromide, 2,2′,5,5′-tetrachlorobiphenyl (PCB52) | 13A7, 14A3, 14A5, 33C3, 33C4, 33C5, 33C6, 33C7, 33D3, 34A6, 35A1, 35A2, 35A3, 35A4, 35A5, 35B1, 35B2, 35B3, 35C1 | [ |
| Drug | Rifampicine, Lansoprazole, primaquine, phenobarbital | 13A7, 31A3, 35A1, 35A2, 35A3, 35A4, 35A5, 35C1 | [ |
| Hormone | Progesterone, 17-β-estradiol | 25A2, 25A6, 29A2, 37A1, 37B1 | [ |
| Metal ion | Zinc, mercury, copper, arsenic, aluminum, cadmium | 13A4, 13A5, 13A6, 13A7, 14A4, 29A2, 33C5, 33C7, 34A9, 35A2 | [ |
| Nanoparticle | Silver and titane nanoparticles | 35A2 | [ |
| Organic compound | Acrylamide, pyrazole | 13A12; 31A1, 31A3 | [ |
| Pesticide | Glyphosate, paraquat, endosulfan, cyperméthrine, chlorpyrifos, dichlorvos, dichlorodiphenyltrichloroethane (DDT), pyridazine, rotenone, atrazine, fenitrothion, thiabendazole | 22A1, 29A2, 34A9, 35A1, 35A2, 35A5, 35B1, 35B2, 35B3, 35C1, 35D1 | [ |
| Phtalate | Diethylhexylphtalate (DEHP) | 35A2 | [ |
| Polycyclic aromatic hydrocarbons | Beta-naphthoflavone, fluoranthene | 14A5, 35A1, 35A2, 35A3, 35A4, 35A5, 35B1, 35B2, 35C1, 37B1 | [ |
| Phenol/Polyphenol | Bisphenol A, tetrabromobisphenol A, resveratrol | 13A6, 13A7, 35A2 | [ |
Metabolism of xenobiotics by C. elegans: implication of P450s.
| Xenobiotic | Metabolite(s) | Reaction(s) | P450(s) Involved | Ref. |
|---|---|---|---|---|
| 2,2′,5,5′-tetrachlorobiphenyl (PCB52) | 3-,4- or 6- hydroxy-PCB52 | Aromatic hydroxylations | 14A members, 34A6 | [ |
| Thiabendazole (TB) | 5-hydroxy-TB | Aromatic hydroxylation | 35D1 | [ |
| Tolbutamide (TA) | Hydroxy-TA | C-H bond hydroxylation | 34A9, 34A10 and 36A1 | [ |
| Amitriptyline | Nortriptyline | Oxidative | Many P450s | [ |
| Dextromethorphan | Dextrorphan | Many P450s | [ | |
| Diclofenac | 4′-hydroxy-diclofenac | Aromatic hydroxylation | n.d. | [ |
| Nifedipine | Oxidized nifedipine | Dehydrogenation | n.d. | [ |
| Clomipramine | Norclomipramine | n.d. | [ |
n.d. not determined.
Figure 3Oxidations of xenobiotics by C. elegans (arrows indicate the oxidation site(s)).
Implication of P450s in the biological effects of xenobiotics on C. elegans.
| Xenobiotic | Biological Effect(s) | P450(s) Involved | P450 Role | Ref. |
|---|---|---|---|---|
| Aflatoxine B1 | DNA damage, growth inhibition | n.d. P450 reductase involved | Toxic activation | [ |
| Tetrabromobisphenol A | Toxicity | 13A7 | Detoxication | [ |
| 3-bromopyruvate | Toxicity | 35A1, 35A2, 35A4, 35B3, 35C1 | Detoxication | [ |
| Fenitrothion | Toxicity | 35A2 | Toxic activation | [ |
| Benzo(a)pyrene | Toxicity | 35A2, 35A3, 35A5 | Toxic activation | [ |
n.d. not determined.
Data presently reported on each C. elegans P450.
| Family | P450s | Endogenous Function(s) | Inducers | Xenobiotic(s) Metabolized | Ref. |
|---|---|---|---|---|---|
| 13 | 13A1 | - | - | - | - |
| 13A2 | - | - | - | - | |
| 13A3 | - | - | - | - | |
| 13A4 | - | Cadmium | - | [ | |
| 13A5 | Dauer larvae and long-lived state | Cadmium | - | [ | |
| 13A6 | - | Cadmium | - | [ | |
| 13A7 | Dauer larvae and long-lived state | Ethidium | Tetrabromobisphenol A | [ | |
| 13A8 | - | Caffeine | - | [ | |
| 13A10 | - | - | - | - | |
| 13A11 | - | - | - | - | |
| 13A12 | Lipid metabolism/fat content | Acrylamide | - | [ | |
| 13B1 | - | Ethanol | - | [ | |
| 13B2 | - | - | - | - | |
| 14 | 14A1 | Dauer larvae and long-lived state | Caffeine | PCB52 | [ |
| 14A2 | - | Caffeine | PCB52 | [ | |
| 14A3 | Dauer larvae and long-lived state | PCB52 | PCB52 | [ | |
| 14A4 | - | Caffeine | PCB52 | [ | |
| 14A5 | - | Beta-naphthoflavone | PCB52 | [ | |
| 22 | 22A1 (DAF-9) | Survival/life span | Atrazine | - | [ |
| 23 | 23A1 | - | - | - | - |
| 25 | 25A1 | - | Ethanol | - | [ |
| 25A2 | - | Ethanol | - | [ | |
| 25A3 | - | - | - | - | |
| 25A4 | - | - | - | - | |
| 25A6 | - | Progesterone | - | [ | |
| 29 | 29A1 | - | - | - | - |
| 29A2 | - | Ethanol | - | [ | |
| 29A3 | Dauer larvae | - | - | [ | |
| 29A4 | - | - | - | - | |
| 31 | 31A2 | Embryonic development | - | - | [ |
| 31A3 | Embryonic development | Atrazine | - | [ | |
| 31A5 | - | - | - | ||
| 32 | 32A1 | Larval development | Caffeine | - | [ |
| 32B1 | Larval development/dauer formation | Ethanol | - | [ | |
| 33 | 33A1 | - | - | - | - |
| 33B1 | - | - | - | - | |
| 33C1 | Larval development/dauer formation | - | - | [ | |
| 33C2 | Larval development/dauer formation | - | - | [ | |
| 33C3 | - | Caffeine | - | [ | |
| 33C4 | - | Caffeine | - | [ | |
| 33C5 | - | Cadmium | - | [ | |
| 33C6 | - | Caffeine | - | [ | |
| 33C7 | - | CadmiumCaffeine | - | [ | |
| 33C8 | - | - | - | - | |
| 33C9 | - | Caffeine | - | [ | |
| 33C11 | - | - | - | - | |
| 33C12 | - | - | - | - | |
| 33D1 | Larval development/dauer formation | - | - | [ | |
| 33D3 | - | Ethidium bromide | - | [ | |
| 33E1 | - | Caffeine | - | [ | |
| 33E2 | - | Caffeine | - | [ | |
| 33E3 | Morphology | Caffeine | - | [ | |
| 33E4 | - | Caffeine | - | [ | |
| 34 | 34A1 | - | - | - | - |
| 34A2 | Dauer formation | - | - | [ | |
| 34A4 | - | Ethanol | - | [ | |
| 34A5 | Dauer formation | - | - | [ | |
| 34A6 | Dauer formation | Ethanol | PCB52 | [ | |
| 34A7 | Dauer formation | Caffeine | - | [ | |
| 34A8 | Dauer formation | - | - | [ | |
| 34A9 | Dauer formation | Caffeine | Tolbutamide | [ | |
| 34A10 | - | - | Tolbutamide | [ | |
| 35 | 35A1 | Lipid metabolism/fat content | Atrazine | 3-bromopyruvate | [ |
| 35A2 | Reproduction | Aluminum, arsenic, cadmium, copper, mercury, zincAtrazine, dichlorvos, dichlorodiphenyltrichloroethane (DDT), rotenone, fenitrothion | 3-bromopyruvate, fenitrothion, | [ | |
| 35A3 | Lipid metabolism/fat content | Beta-naphthoflavone | B(a)P | [ | |
| 35A4 | Lipid metabolism/fat content | Beta-naphthoflavone | 3-bromopyruvate | [ | |
| 35A5 | Lipid metabolism/fat content | Atrazine | B(a)P | [ | |
| 35B1 | Dauer formation | Atrazine | - | [ | |
| 35B2 | Dauer formation | Atrazine | - | [ | |
| 35B3 | - | Ethidium bromide | 3-bromopyruvate | [ | |
| 35C1 | - | Atrazine | 3-bromopyruvate | [ | |
| 35D1 | - | Thiabendazole | Thiabendazole | [ | |
| 36 | 36A1 | - | Ethanol | Tolbutamide | [ |
| 37 | 37A1 | Lipid metabolism/fat content | Progesterone | - | [ |
| 37B1 | Lipid metabolism/fat content | Ethanol | - | [ | |
| 42 | 42A1 | - | - | - | - |
| 43 | 43A1 | - | Caffeine | - | [ |
| 44 | 44A1 | - | - | - | - |